atbtherapeutics

What we do: ATB Therapeutics is a pioneering Belgian biopharmaceutical company dedicated to developing innovative therapies for cancer, with a particular focus on hard-to-treat and refractory forms of the disease. Our core innovation is the 'atbody,' a novel biologic format that combines antibodies with toxins to optimize the therapeutic window and overcome cancer cell resistance. Leveraging our proprietary, plant-based atbiofarm technology, we enable single-step manufacturing of these atbodies, aiming to deliver increased potency, stability, and targeted exposure. Our mission is to broaden treatment options for patients facing the most challenging cancers, and we are also exploring applications in auto-immune diseases. We operate at the forefront of biotechnology, committed to transforming cancer treatment through scientific excellence and cutting-edge innovation[1][3][4].

Where we are located: Our headquarters is located at Suzanne Tassierstraat 1, 9052 Gent, Belgium. This central location in Flanders positions us within one of Europe’s leading biotech hubs, fostering collaboration and access to top talent in the life sciences sector.

Short history: ATB Therapeutics was founded in 2018 with the vision to redefine cancer therapy through novel biologic formats. Since our inception, we have focused on advancing our proprietary atbody technology and building a robust pipeline of next-generation therapeutics. Our milestones include the development of the atbiofarm platform, which allows for efficient, scalable production of our innovative biologics. While specific founding details beyond the year are not publicly highlighted, our rapid progress and recent inclusion in the portfolio of EQT Group’s LSP 7 fund in 2024 underscore our growth and potential in the biopharmaceutical landscape[2][3].

Organization & culture: ATB Therapeutics is a compact, dynamic organization with a team of 22 passionate experts. We cultivate a culture of scientific curiosity, collaboration, and diversity, where every team member’s contribution is valued. Our environment is designed to encourage innovation, with a strong emphasis on research and development as the foundation for overcoming oncology challenges. We believe that a multidisciplinary team, united by a shared commitment to improving patient lives, is key to our success. Our values—innovation, collaboration, and scientific rigor—guide our daily work and long-term vision.

Recent developments: In 2024, ATB Therapeutics was added to the portfolio of EQT Group’s LSP 7 fund, marking a significant step in our company’s growth and validating our innovative approach to cancer therapy[2]. This partnership highlights our potential to scale and bring transformative treatments to patients worldwide. While we continue to advance our pipeline, we remain focused on scientific excellence and the development of life-changing therapies for those in need.